Hari Mohan, a 45 year old clerk at the MTNL's New Delhi establishment, could not conceal his dismay. “At a time when inflation is at 7.5 per cent, the 6.75 per cent that they are referring to is peanuts,” he says with reference to an article in the newspaper about the bonds issued to investors in lieu of UTI's US-64 schemes unit. Incidentally, the Unit 64 scheme is maturing on May 31, 2008. Hari Mohan is not alone, 83 per cent of 20 million unit holders of the then US-64 schemes stood party to this mass exodus. In April 2003 when the sordid US-64 saga was laid to rest by the then NDA government, it was decided that investors of US-64 be given the option of 6.75 per cent tax-free bonds or liquidation of their holding. Investors holding up to 5,000 units would be offered Rs 12 and for additional holdings they would be offered Rs 10 per unit. “You get paid at the face value for a scheme you held for almost 40 years. So the plan B with tax-free advantage looked lucrative. It was an enforced error,” says Mohan. Rightly said, the tax-free option did look rewarding, then. But it turned out to be one of the most horrendous investment decisions one could have ever made. Consider this - Rs 1 lakh invested (shifted) to the bonds would fetch Rs 1.38 lakh in a span of year (May 31, 2008). Had this amount been invested in other existing schemes of UTI, say UTI Balanced, the amount would have swollen to Rs. 3.43 lakh. Even if you consider the conservative UTI Mahila Unit Scheme, which invests 66 per cent in debt, you would have been sitting on a pile of Rs 2.50 lakh. A little bit of conscious and judiciously decision and the corpus would been a pharaohcious Rs. 11.86 lakh, if invested in Reliance Growth.
(by value research)
Thursday, May 22, 2008
In The Pink Of Health
The struggling pharma funds have staged a smart recovery after a lackluster performance for the past few years. The BSE Healthcare Index, that crashed along with the rest of the market in January 2008, has recovered quickly and gained 17.7 per cent in the past three months. In 2005-06, the Equity: Pharma category was the worst performing category in the equity class of mutual funds. The average return of the category in the three-year period (2005-07) stood at 20 per cent, a far cry from the 47.3 per cent return by equity diversified funds. This small category with
five funds has also witnessed a steep fall in assets under management since then. The combined AUM that stood at Rs 623 crore in January 2005 is down 60 per cent to Rs 254 crore, Reliance Pharma alone accounting for Rs 122 crore. Surprisingly, none of the five funds in this category have a large-cap heavy portfolio.
However, in the three month period ended May 2, 2008, the pharma category of mutual funds bounced back. In the period, the average return of pharma funds stood at 10.28 per cent, at a time when almost all equity categories posted negative returns. Reliance Pharma, the category topper for the past two years could not manage to retain its position. Magnum Pharma took very concentrated bets with 48 per cent of the portfolio in just two stocks. As a result, it could not capitalise on the surge in the sector and was the only one to post negative returns.
Fund
Return (%)*
UTI Pharma & Healthcare
16.35
JM Healthcare Sector
15.18
Franklin Pharma
13.92
Reliance Pharma
6.35
Magnum Pharma
-0.4
Category Average
10.28
*February 2- May 2, 2008
The robust numbers declared by various pharma companies helped the sector rally. For instance, Ranbaxy Laboratories, the second largest aggregated holding of these funds, reported a 60 per cent growth in its PAT over 2007-08. Smaller players like Glenmark Pharma reported a 188 per cent rise in profits on a y-o-y basis.
Stocks
Return (%)*
Glenmark Pharmaceuticals
39.82
Ranbaxy Laboratories
33.87
Sun Pharmaceutical Industries
28.98
Glaxosmithkline Pharmaceuticals
25.60
Biocon
23.66
*February 2- May 2, 2008
(by valueresearch)
five funds has also witnessed a steep fall in assets under management since then. The combined AUM that stood at Rs 623 crore in January 2005 is down 60 per cent to Rs 254 crore, Reliance Pharma alone accounting for Rs 122 crore. Surprisingly, none of the five funds in this category have a large-cap heavy portfolio.
However, in the three month period ended May 2, 2008, the pharma category of mutual funds bounced back. In the period, the average return of pharma funds stood at 10.28 per cent, at a time when almost all equity categories posted negative returns. Reliance Pharma, the category topper for the past two years could not manage to retain its position. Magnum Pharma took very concentrated bets with 48 per cent of the portfolio in just two stocks. As a result, it could not capitalise on the surge in the sector and was the only one to post negative returns.
Fund
Return (%)*
UTI Pharma & Healthcare
16.35
JM Healthcare Sector
15.18
Franklin Pharma
13.92
Reliance Pharma
6.35
Magnum Pharma
-0.4
Category Average
10.28
*February 2- May 2, 2008
The robust numbers declared by various pharma companies helped the sector rally. For instance, Ranbaxy Laboratories, the second largest aggregated holding of these funds, reported a 60 per cent growth in its PAT over 2007-08. Smaller players like Glenmark Pharma reported a 188 per cent rise in profits on a y-o-y basis.
Stocks
Return (%)*
Glenmark Pharmaceuticals
39.82
Ranbaxy Laboratories
33.87
Sun Pharmaceutical Industries
28.98
Glaxosmithkline Pharmaceuticals
25.60
Biocon
23.66
*February 2- May 2, 2008
(by valueresearch)
Biggest of them All
Three months after its launch in January 2008, Reliance Natural Resources Fund has emerged as the India's largest equity fund with assets under management (AUM) of Rs 5,589 crore (April 2008). The fund overtook ICICI Prudential Infrastructure Fund which topped the charts in March with an AUM of Rs 5,390 crore. It was not too long ago that the AUM of Reliance Mutual Fund touched Rs 1 lakh crore. In January 2008, when most investors refrained from investing and fund houses had a tough time mobilising funds,Reliance Natural Resources managed to collect a whopping Rs 5,660 crore. It was the second largest collection by an equity mutual fund; the top place occupied by another Reliance family member - Reliance Equity, which mobilised Rs 5,790 crore in 2006. The equity funds from the Reliance stable do not hesitate from taking aggressive cash calls. This fund is no exception as the fund currently maintains extremely high cash levels. Though the cash component decreased in April to 53 per cent from March levels of 62 per cent, the fund manager is still waiting for the right opportunity to invest in stock markets. The fund's AUM has eroded by Rs 71 crore since launch but the high cash strategy helped the fund protect the downside. The fund posted a positive return of 0.5 per cent since February 26, 2008 (first NAV date), at a time when the average return of the equity diversified funds has been (-) 6 per cent (February 26 - May 8, 2008). Looking at the portfolio, various large cap stocks like Reliance Industries , ONGC and ACC have been included. However, the fund is quite keen on diversifying by investing in securities abroad. As per its mandate, the fund can invest up to 35 per cent of its assets in foreign securities. The exposure to such stocks has been increased in a short span and close to 7 per cent of its assets account for such foreign securities. Though the investment in such assets is small, the fund manager has selected companies like Arcelor Mittal (world's largest steel producer) and Freeport McMoRan Copper & Gold (world's largest publicly traded copper company). The fund's maximum international investment is in companies engaged in the global water industry. This investment is through PowerShares Water Resources ETF, a water index based international ETF.
(by valueresearch)
(by valueresearch)
Subscribe to:
Posts (Atom)